
Blockbuster potential drugs ruled the 2024 pipeline with 53% rise over 2023
The number of late-stage drug candidates with peak sales forecasts exceeding $1bn rose significantly last year, buoyed in part by the lucrative weight loss and diabetes markets, analysis shows. In its annual ‘Measuring the Return from Pharmaceutical …